Rhythm Pharmaceuticals Inc (RYTM) — Who's Buying and Selling (13F, Q2 2026)

RYTM ranks #2073 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

RYTM is a top-conviction position for Checkpoint Capital L.P. — at 33.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in RYTM belongs to Ra Capital Management, L.p., but the position matters far more to Checkpoint Capital L.P., who has 33.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its RYTM position for two straight quarters, increasing it by $124.9M to reach $145.4M today.

Driehaus Capital Management LLC has trimmed its RYTM position for two straight quarters, cutting it by $123.2M while still holding $14.4M.

RYTM is down 1.3% today, but institutions show net buying of $1.3B this quarter — a divergence between today's price move and the underlying institutional flow.

RYTM reported a net loss of $205.3M over the trailing twelve months.

• Not yet profitable — net loss of $205.3M over the trailing twelve months
• Revenue grew 53.5% year over year
• Net income declined year over year, from -$183.1M to -$205.3M
• Operating cash flow was negative, using $115.7M in cash
• Current ratio of 4.41x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.51x equity — within a conventional range